Inhibition of human IL 2 production by MDP and derivatives

Abstract

In the present study, well-defined immunomodulatory synthetic glycopeptides were used to investigate putative regulatory mechanisms of in vitro IL 2 production by normal human peripheral blood mononuclear cells. MDP (muramyl dipeptide) and two of its structural analogs, murabutide and MDP-DD, were shown to inhibit the in vitro PHA-induced IL 2 production in a majority of normal individuals tested. Involvement of prostaglandins in such an inhibitory effect was suggested by the fact that indomethacin completely abrogated the MDP-induced suppression. There was, however, some evidence indicating that the inhibition induced by the synthetic glycopeptides and that induced by PGE2 were somewhat different. Indeed, although the PGE2-induced suppression of IL 2 production was completely reversed by preirradiation of PBMNC, this was not observed for the MDP-dependent inhibition. In addition, PMA was able to abrogate the suppression induced by MDP, whereas it increased that of PGE2. From these data we propose that at least two independent pathways in the regulation of human IL 2 production exist: a one-signal pathway already described in which PGE2 directly triggers a radiosensitive suppressor T cell subset; and a second pathway with two signals, one given by PGE2 and a second one given by agents such as muramyl peptides. These two signals are required to activate a radioresistant suppressor cell subset.